Date: 2016-10-24
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Solid Biosciences (USA - MA) Solid GT (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
Disease:
Details: * On October 24, 2016, Solid Biosciences and its subsidiary, Solid GT, announced that the company plans to initiate clinical studies for SGT-001 in 2017. To support the advancement of its clinical program, Solid has opened an office in London, England. Spearheaded by leading DMD clinician Valeria Ricotti, M.D., Ph.D., (formerly University College London, Institute of Child Health and Great Ormond Street Hospital) and patient advocate Kerry Rosenfeld, Solid’s London team will work closely with the European DMD community to help realize its goal of bringing meaningful therapies to patients around the world.
Financial terms:
Latest news:
